Valbonne, France, July 19, 2018, 5.45pm CEST
TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today reports its financial information for the 2nd quarter of 2018.
Cash position and revenue as of June 30, 2018
As at June 30, 2018, the cash and cash equivalents amounted to €4.4 million, after partial pre-financing of the 2018 Research Tax Credit for €0.6 million and drawing of five monthly tranches of the amended financing program of notes convertible into shares with share subscription warrants (OCABSA) for a nominal amount of €6.6 million. As at June 30, 2018 (unchanged as of today), 56 OCA remained unconverted, for a nominal amount of €5.6 million.
As a reminder, this OCABSA program consists of monthly installments for a nominal amount of €1.2 million each at TxCell’s sole discretion, for a total financing of up to €15 million. It should enable the Company to finance its activities until early 2019.
TxCell is actively working towards securing a longer-term financing solution, such as a strategic partnership and/or an equity offering, depending on market conditions. The Company may interrupt these monthly OCABSA issuances at any time.
As expected, TxCell did not generate any revenue during the second quarter 2018.
 Unaudited and not subject to approval by the board of directors
 Except for the first installment which amounted to €1.8 million in February 2018.